POLB 001: tackling cytokine storms before they start
Drug Target Review
MAY 23, 2025
As the biotech sector races to improve the tolerability of these revolutionary treatments, Poolbeg Pharma has a novel solution: an oral therapy, POLB 001, to block the development of CRS, by limiting inflammation without affecting the anti-cancer immune responses that are vital for effective immunotherapies.
Let's personalize your content